Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Thermo Fisher Scientific Inc / Equity Bottom-Up

<ul><li>Thermo Fisher Scientific's second-quarter 2025 earnings showcased a company navigating a challenging macroeconomic environment positively and prudently.</li><li>The company reported revenue growth of 3% to $10.85 billion and a 1% increase in adjusted operating income to $2.38 billion.</li><li>Its adjusted earnings per share (EPS) was $5.36, signaling an ability to surpass internal guidance despite headwinds, primarily from tariffs affecting operations in China and broader policy uncertainties.</li></ul>

Thermo Fisher Scientific's second-quarter 2025 earnings showcased a company navigating a challenging macroeconomic environment positively and prudently.The company reported revenue growth of 3% to $10.85 billion and a 1% increase in adjusted operating income to $2.38 billion.Its adjusted earnings per share (EPS) was $5.36, signaling an ability to surpass internal guidance despite headwinds, primarily from tariffs affecting operations in China and broader policy uncertainties.

Thermo Fisher Scientific: Emerging Market Potential & Resilience As A Key To Its Growth Strategy!

<ul><li>Thermo Fisher Scientific's Q1 2025 earnings report exhibits both strengths and challenges, reflecting the complex macroeconomic landscape.</li><li>The company reported a solid revenue of $10.36 billion and an adjusted operating income of $2.27 billion.</li><li>Their adjusted operating margin stood at 21.9%, with an adjusted EPS of $5.15, reflecting a 1% year-over-year growth.</li></ul>

Thermo Fisher Scientific's Q1 2025 earnings report exhibits both strengths and challenges, reflecting the complex macroeconomic landscape.The company reported a solid revenue of $10.36 billion and an adjusted operating income of $2.27 billion.Their adjusted operating margin stood at 21.9%, with an adjusted EPS of $5.15, reflecting a 1% year-over-year growth.

Thermo Fisher Scientific: Latest Expansion in Pharmaceutical Services Driving Our Optimism!

<ul><li>For the fourth quarter of 2024, Thermo Fisher Scientific reported a 5% year-over-year growth in revenue, reaching $11.4 billion, alongside a 7% increase in adjusted operating income, which totaled $2.72 billion.</li><li>This resulted in an adjusted operating margin expansion by 50 basis points to 23.9%.</li><li>Moreover, adjusted earnings per share (EPS) grew by 8% to $6.10.</li></ul>

For the fourth quarter of 2024, Thermo Fisher Scientific reported a 5% year-over-year growth in revenue, reaching $11.4 billion, alongside a 7% increase in adjusted operating income, which totaled $2.72 billion.This resulted in an adjusted operating margin expansion by 50 basis points to 23.9%.Moreover, adjusted earnings per share (EPS) grew by 8% to $6.10.

Thermo Fisher Scientific: Will Its Shift Toward Contract Research and Manufacturing Pay Off? - Major Drivers

<ul><li>Thermo Fisher Scientific's third-quarter results of 2024 demonstrated robust financial performance amid a challenging environment, driven by a mix of solid core business operations and strategic initiatives.</li><li>The company reported quarterly revenue of $10.6 billion with an adjusted operating income amounting to $2.36 billion, reflecting an adjusted operating margin of 22.3%.</li><li>The adjusted earnings per share (EPS) was reported at $5.28, underscoring their capacity to generate consistent shareholder value.</li></ul>

Thermo Fisher Scientific's third-quarter results of 2024 demonstrated robust financial performance amid a challenging environment, driven by a mix of solid core business operations and strategic initiatives.The company reported quarterly revenue of $10.6 billion with an adjusted operating income amounting to $2.36 billion, reflecting an adjusted operating margin of 22.3%.The adjusted earnings per share (EPS) was reported at $5.28, underscoring their capacity to generate consistent shareholder value.

Thermo Fisher Scientific: Expansion of Clinical Research & Pharma Services Integration Driving Our Bullishness!  - Major Drivers

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

United States

Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals.  The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Thermo Fisher Scientific Inc (TMO US)

Thermo Fisher Scientific: Emerging Market Potential & Resilience As A Key To Its Growth Strategy!

Thermo Fisher Scientific's second-quarter 2025 earnings showcased a company navigating a challenging macroeconomic environment positively and...

Baptista Research

Thermo Fisher Scientific: Latest Expansion in Pharmaceutical Services Driving Our Optimism!

Thermo Fisher Scientific's Q1 2025 earnings report exhibits both strengths and challenges, reflecting the complex macroeconomic landscape. The...

Baptista Research

Thermo Fisher Scientific: Will Its Shift Toward Contract Research and Manufacturing Pay Off? - Major Drivers

For the fourth quarter of 2024, Thermo Fisher Scientific reported a 5% year-over-year growth in revenue, reaching $11.4 billion, alongside a 7%...

Baptista Research

Thermo Fisher Scientific: Expansion of Clinical Research & Pharma Services Integration Driving Our Bullishness! - Major Drivers

Thermo Fisher Scientific's third-quarter results of 2024 demonstrated robust financial performance amid a challenging environment, driven by a mix...

Baptista Research

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)